 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Scios Inc.
 |
Scios Inc. |
 |
 |
 |
NEWS FROM THE WIRES |
 |
European single stock futures patchy to date Aug 13 2001 07:12 AM PDT
Scios says Natrecor gets FDA approval Aug 13 2001 05:28 AM PDT
Biotech shares lose nearly half of Q2 gains Jul 13 2001 01:24 PM PDT
> More WIRE STORIES about this company
NEWS FROM THE STANDARD |
 |
FDA Catches Fed's Disease
Jul 11 2001 06:21 AM PDT
PROFILE |
 |
Get to know Scios! The biopharmaceutical firm (whose name means "to know" in Greek) develops protein-based small-molecule drugs targeting heart conditions, inflammatory diseases, and Alzheimer's disease. Its drug candidates, which are in various stages of research and development, include lead candidate Natrecor (congestive heart failure), SCIO-469 (rheumatoid arthritis), Fiblast (wound healing), and beta-amyloid modulators (Alzheimer's). Scios has joint development agreements with such companies as Abbott Laboratories and Eli Lilly to research and market its products. It also sells psychiatric drugs from GlaxoSmithKline, Johnson & Johnson subsidiary Janssen Pharmaceutical, and others.
COMPETITION |
 |
CV Therapeutics, Inc. (CVTX)
Endo Pharmaceuticals Holdings, Inc. (ENDP)
Merck & Co., Inc. (MRK)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 12.60
1-Yr. Sales Growth: (79.3)%
Employees: 194
Revenue per employee: $64,948.45
KEY PEOPLE |
 |
Richard B. Brewer
CEO
David W. Gryska
CFO
CONTACT INFO |
 |
820 W. Maude Ave.
Sunnyvale, CA 94086
US
Phone: 408-616-8200
Fax: 408-616-8206
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |